BFS
VKTX icon

Burkett Financial Services’s Viking Therapeutics VKTX Stock Holding History

Burkett Financial Services’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.52K Hold
200
– – ﹤0.01% 316
2026
Q2 		$7.8K Hold
200
– – ﹤0.01% 192
2026
Q1 		$6.51K Hold
200
– – ﹤0.01% 182
2025
Q4 		$7.04K Hold
200
– – ﹤0.01% 170
2025
Q3 		$5.26K Hold
200
– – ﹤0.01% 170
2025
Q2 		$5.3K Hold
200
– – ﹤0.01% 166
2025
Q1 		$4.83K Hold
200
– – ﹤0.01% 189
2024
Q4 		$8.05K Buy
+200
New +$11.4K ﹤0.01% 147

Other funds holding VKTX

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
NWMP
Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

Burkett Financial Services's VKTX Position: Q3 2026 in Review

Burkett Financial Services held its Viking Therapeutics (VKTX) position steady in Q3 2026 at 200 shares worth $6.52K. The position accounts for ﹤0.01% of the portfolio, ranked #316.

Burkett Financial Services first reported a position in VKTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $8.05K in Q4 2024. 11 funds tracked by Wall St. Rank hold VKTX as of Q3 2026.

  • Burkett Financial Services held 200 shares of Viking Therapeutics worth $6.52K as of Q3 2026.
  • Burkett Financial Services left its Viking Therapeutics share count unchanged in Q3 2026.
  • Viking Therapeutics made up ﹤0.01% of Burkett Financial Services's portfolio in Q3 2026, its #316 holding.
  • Burkett Financial Services first reported a position in Viking Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Burkett Financial Services's Viking Therapeutics position peaked at $8.05K in Q4 2024.
  • 11 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2026.

Based on Burkett Financial Services's 13F filing for Q3 2026, filed 1 Oct 2026.